

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

**RE-ALLOCATION AND USE OF NET PROCEEDS FROM THE PLACEMENT OF 80,450,200
ORDINARY SHARES IN THE CAPITAL OF CLEARBRIDGE HEALTH LIMITED**

The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements dated 29 July 2019, 15 August 2019 and 19 August 2019 (the “**Announcements**”), in relation to the placement of 80,450,200 new ordinary shares in the capital of the Company (the “**Placement**”).

Unless otherwise defined, capitalised terms used herein shall bear the same meaning ascribed to them in the Announcements.

The Board wishes to update that, following a review of the Group’s current operating environment, cash flow as well as investment and expansion plans, the Company has decided to re-allocate S\$2,695,000 of the Net Proceeds originally allocated for the expansion of the Company’s businesses through mergers and acquisitions, joint ventures, strategy collaborations and/or investment, or organically in Asia, to be utilised for the general working capital purposes of the Group (the “**Re-Allocation**”). The Board is of the view that the Re-Allocation is in the best interests of the Company and Shareholders as the Re-Allocation will enable the Group to effectively deploy available cash to support the operations of the Group.

Following the Re-Allocation, the use of the Net Proceeds as at the date of this announcement is set out as follows:

	Amount allocated at Placement (S\$’000)	Amount utilised as at 12 April 2024 (S\$’000)	Re-Allocation (S\$’000)	Amount utilised from 12 April 2024 to the date of this announcement (S\$’000)	Balance (S\$’000)
Expansion of the Company’s businesses through mergers and acquisitions, joint ventures, strategy collaborations and/or investment, or organically in Asia	7,893	(4,872)	(2,695)	(326)	-
General working capital purpose	3,383	(3,383) ⁽¹⁾	2,695	-	2,695
Total	11,276	(8,255)	-	(326)	2,695

Note:

(1) Utilised mainly for operating expenses of the Group.

Save as disclosed in this announcement on the Re-Allocation, the use of the Net Proceeds is in accordance with the intended use as set out in the Announcement. The Company will continue to make periodic announcements on the utilisation of the balance of the Net Proceeds as and when such net proceeds are materially disbursed or utilised. The Company will also provide a status report on the use of the Net Proceeds in its annual report(s) and financial results announcement(s).

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer
30 April 2024

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**"), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Goh Mei Xian, Director, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.